MX2023003836A - Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas. - Google Patents

Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.

Info

Publication number
MX2023003836A
MX2023003836A MX2023003836A MX2023003836A MX2023003836A MX 2023003836 A MX2023003836 A MX 2023003836A MX 2023003836 A MX2023003836 A MX 2023003836A MX 2023003836 A MX2023003836 A MX 2023003836A MX 2023003836 A MX2023003836 A MX 2023003836A
Authority
MX
Mexico
Prior art keywords
host cell
methods
purification processes
reducing host
protein content
Prior art date
Application number
MX2023003836A
Other languages
English (en)
Inventor
Brian David Bowes
Lara Ellen Krebs
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023003836A publication Critical patent/MX2023003836A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a métodos para reducir el contenido de proteínas de célula huésped en una preparación de proteína producida de forma recombinante en una célula huésped en el proceso de fabricación de proteínas destinadas a la administración a un paciente.
MX2023003836A 2020-10-02 2021-10-04 Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas. MX2023003836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086915P 2020-10-02 2020-10-02
PCT/US2021/053318 WO2022072919A1 (en) 2020-10-02 2021-10-04 Methods for reducing host cell protein content in protein purification processes

Publications (1)

Publication Number Publication Date
MX2023003836A true MX2023003836A (es) 2023-04-14

Family

ID=78621988

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023003836A MX2023003836A (es) 2020-10-02 2021-10-04 Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.
MX2023003863A MX2023003863A (es) 2020-10-02 2021-10-04 Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003863A MX2023003863A (es) 2020-10-02 2021-10-04 Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped.

Country Status (17)

Country Link
US (2) US20230374063A1 (es)
EP (2) EP4222160A1 (es)
JP (2) JP2023544399A (es)
KR (2) KR20230078748A (es)
CN (2) CN116348486A (es)
AR (1) AR123688A1 (es)
AU (2) AU2021355521A1 (es)
BR (1) BR112023004871A2 (es)
CA (2) CA3192910A1 (es)
CL (1) CL2023000961A1 (es)
CO (1) CO2023004265A2 (es)
EC (1) ECSP23024034A (es)
IL (2) IL301572A (es)
MX (2) MX2023003836A (es)
PE (1) PE20231507A1 (es)
TW (1) TW202229307A (es)
WO (2) WO2022072919A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213526B2 (en) 2014-03-21 2019-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
WO2012136552A1 (en) * 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
JP7116256B1 (ja) * 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片

Also Published As

Publication number Publication date
CO2023004265A2 (es) 2023-04-27
CN116348486A (zh) 2023-06-27
EP4222160A1 (en) 2023-08-09
BR112023004871A2 (pt) 2023-04-25
AU2021355518A9 (en) 2024-02-08
EP4222159A1 (en) 2023-08-09
CA3193722A1 (en) 2022-04-07
JP2023544399A (ja) 2023-10-23
ECSP23024034A (es) 2023-04-28
AU2021355521A1 (en) 2023-05-11
AU2021355518A1 (en) 2023-06-08
KR20230078748A (ko) 2023-06-02
WO2022072934A1 (en) 2022-04-07
US20230374063A1 (en) 2023-11-23
CL2023000961A1 (es) 2023-11-03
IL301572A (en) 2023-05-01
KR20230061462A (ko) 2023-05-08
AR123688A1 (es) 2023-01-04
JP2023545019A (ja) 2023-10-26
CA3192910A1 (en) 2022-04-07
TW202229307A (zh) 2022-08-01
PE20231507A1 (es) 2023-09-26
CN116547292A (zh) 2023-08-04
WO2022072919A1 (en) 2022-04-07
IL301584A (en) 2023-05-01
MX2023003863A (es) 2023-04-14
US20230406914A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
MX2023003836A (es) Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.
JP7116823B2 (ja) 新規なトリプシンアイソフォームおよびそれらの使用
MX2015009908A (es) Metodos para producir dicetopiperazinas y composiciones que contienen dicetopiperazinas.
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
MX2012007497A (es) Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
MX354156B (es) Dipeptido que comprende un aminoacido no proteogenico.
CN104593318B (zh) 一种用于细胞培养基的玉米活性肽添加剂
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
WO2018038577A8 (ko) 7-아미노세팔로스포란산의 고농도 생산 재조합 아크레모니움 크리소제눔 균주의 제조방법 및 이 방법으로 제조된 균주
CN113555060A (zh) 具有降血糖、降血压活性的山羊奶酪蛋白肽的制备方法
WO2020140021A3 (en) Process for producing, isolating, and purifying modified recombinant proteins
Man et al. Optimization of DsbA purification from recombinant Escherichia coli broth using Box-Behnken design methodology
CN104151418A (zh) 一种体外重组表达人tarc/ccl17可溶性蛋白的方法
CA2995985A1 (en) Enzymatic fractions with anti-inflammatory activity
CN116636576A (zh) 一种脱苦的高钙活性酪蛋白磷酸肽螯合物及其制备方法
CN118063585A (zh) 一种具有免疫活性的酪蛋白源活性肽及其制备方法和应用
CN104151417A (zh) 一种体外重组表达人ctack/ccl27可溶性蛋白的方法
TH160179B (th) การทำไอดิลโรเนต-2-ซัลฟาเตสให้บริสุทธิ์
RU2009114809A (ru) Способ очистки рекомбинантной стафилокиназы
MX2008002448A (es) Metodo de purificación de proteinas recombinantes con isoformas acidas.